SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(van der Schaaf Rene J)
 

Sökning: WFRF:(van der Schaaf Rene J) > Bioresorbable Scaff...

  • Wykrzykowska, Joanna J (författare)

Bioresorbable Scaffolds versus Metallic Stents in Routine PCI.

  • Artikel/kapitelEngelska2017

Förlag, utgivningsår, omfång ...

  • 2017
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-342873
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-342873URI
  • https://doi.org/10.1056/NEJMoa1614954DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Collaborator Bioresorbable Scaffolds versus Metallic Stents in Routine PCI.
  • BACKGROUND: Bioresorbable vascular scaffolds were developed to overcome the shortcomings of drug-eluting stents in percutaneous coronary intervention (PCI). We performed an investigator-initiated, randomized trial to compare an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in the context of routine clinical practice.METHODS: We randomly assigned 1845 patients undergoing PCI to receive either a bioresorbable vascular scaffold (924 patients) or a metallic stent (921 patients). The primary end point was target-vessel failure (a composite of cardiac death, target-vessel myocardial infarction, or target-vessel revascularization). The data and safety monitoring board recommended early reporting of the study results because of safety concerns. This report provides descriptive information on end-point events.RESULTS: The median follow-up was 707 days. Target-vessel failure occurred in 105 patients in the scaffold group and in 94 patients in the stent group (2-year cumulative event rates, 11.7% and 10.7%, respectively; hazard ratio, 1.12; 95% confidence interval [CI], 0.85 to 1.48; P=0.43); event rates were based on Kaplan-Meier estimates in time-to-event analyses. Cardiac death occurred in 18 patients in the scaffold group and in 23 patients in the stent group (2-year cumulative event rates, 2.0% and 2.7%, respectively), target-vessel myocardial infarction occurred in 48 patients in the scaffold group and in 30 patients in the stent group (2-year cumulative event rates, 5.5% and 3.2%), and target-vessel revascularization occurred in 76 patients in the scaffold group and in 65 patients in the stent group (2-year cumulative event rates, 8.7% and 7.5%). Definite or probable device thrombosis occurred in 31 patients in the scaffold group as compared with 8 patients in the stent group (2-year cumulative event rates, 3.5% vs. 0.9%; hazard ratio, 3.87; 95% CI, 1.78 to 8.42; P<0.001).CONCLUSIONS: In this preliminary report of a trial involving patients undergoing PCI, there was no significant difference in the rate of target-vessel failure between the patients who received a bioresorbable scaffold and the patients who received a metallic stent. The bioresorbable scaffold was associated with a higher incidence of device thrombosis than the metallic stent through 2 years of follow-up. (Funded by Abbott Vascular; AIDA ClinicalTrials.gov number, NCT01858077 .).

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Kraak, Robin P (författare)
  • Hofma, Sjoerd H (författare)
  • van der Schaaf, Rene J (författare)
  • Arkenbout, E Karin (författare)
  • IJsselmuiden, Alexander J (författare)
  • Elias, Joëlle (författare)
  • van Dongen, Ivo M (författare)
  • Tijssen, Ruben Y G (författare)
  • Koch, Karel T (författare)
  • Baan, Jan (författare)
  • Vis, M Marije (författare)
  • de Winter, Robbert J (författare)
  • Piek, Jan J (författare)
  • Tijssen, Jan G P (författare)
  • Henriques, Jose P S (författare)
  • James, StefanUppsala universitet,Institutionen för medicinska vetenskaper,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)stjam367(författare)
  • Uppsala universitetInstitutionen för medicinska vetenskaper (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:New England Journal of Medicine376:24, s. 2319-23280028-47931533-4406

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy